Ann: Appointment of Jozsef Patarica as CEO and Managing Director, page-27

Yes, but we’ve seen many such positive reports from Shaw’s before. This has been a very disappointing stock for many holders, so what will be different this time? A new CEO, yes, and ‘improved efficiencies’ (maybe), but until real results are delivered (problem-free production, nameplate quality, higher sales and exports, etc) this stock will remain an act of faith. There may be good gains for patient holders but this is really the last chance for STA to deliver. No more talk of ‘world-class mine’ etc, please, until such claims are backed up with hard evidence.